Avery Therapeutics, Inc.

What Avery Therapeutics, Inc. does

Avery Therapeutics, Inc. is a privately held, preclinical-stage biotechnology company founded in 2014 and headquartered in Tucson, Arizona, developing immunomodulatory biologic therapeutics for diseases of aging, inflammation, and fibrosis. The company's core platform is an adaptive biologic technology that redirects the immune system — rather than targeting symptoms — to restore organ function, with heart failure as the lead indication. Built on research originating from the University of Arizona and the Southern Arizona VA Health Care Center, the platform has been applied to two pipeline modalities: a bioengineered epicardial patch that induces macrophage-mediated repair in chronically infarcted hearts, and iPSC-derived cardiomyocyte patches. Preclinical efficacy has been demonstrated in swine heart failure models and rat models, with results published in peer-reviewed journals including Nature Communications Biology and Circulation: Heart Failure, and a Phase I clinical trial has been proposed for the lead patch program.

The business is structured around the founder-CEO Jordan Lancaster, PhD, CTO Ronnda Bartel, PhD (30+ years of cell-based therapeutics experience including prior FDA approvals), and CMO/Co-founder Steven Goldman, MD (35+ years in cardiovascular research). The board and Scientific and Medical Advisory Board include operators and academics with multi-billion-dollar exit track records — Leslie Leinwand (co-founder of Myogen and MyoKardia), Emile Nuwaysir (BlueRock Therapeutics, Bayer acquisition), Hansjörg Wyss (Synthes USA, $20B Johnson & Johnson acquisition), and Lawrence Mehren (former CEO of Accelerate Diagnostics). As a pre-revenue company with 1-10 employees and no disclosed funding rounds or distribution channels, Avery has no current commercial revenue and derives its go-to-market path through eventual FDA approval and traditional pharmaceutical/healthcare distribution. Marketing is limited to the company website and a LinkedIn presence focused on recruitment and scientific communication.

Name

Avery Therapeutics, Inc.

Legal name

Avery Therapeutics, Inc.

Website

https://averythera.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Avery Therapeutics is a preclinical-stage, Tucson-based biotech developing an immunomodulatory biologic platform that redirects the immune system to restore organ function, with bioengineered and iPSC-derived cardiac patches targeting chronic heart failure as the lead indication.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Biologic Therapeutics

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Immunomodulatory biologic therapeutics
• Tissue engineered therapeutics
• Cardiac regenerative medicine
• Heart failure biologics
• Cell-based therapeutics

Headquarters

HQ city

Tucson

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Marketing channels2 records

Core offering

Avery Therapeutics is developing an immunomodulatory biologic therapeutics platform that redirects the immune system to restore organ function, targeting diseases of aging, inflammation, and fibrosis. Its lead product candidate is a bioengineered epicardial patch intended to induce macrophage-mediated repair in chronically infarcted hearts, with a Phase I clinical trial proposed. The pipeline also includes iPSC-derived cardiomyocyte patches and other tissue-engineered therapeutic approaches.

Product overview

Avery Therapeutics offers a single, unified product: an immunomodulatory biologic therapeutics platform. This adaptive biologic platform is the core technology from which all therapeutic approaches derive. The platform is applied specifically to heart failure treatment through bioengineered tissue patches that leverage the immunomodulatory mechanism to induce macrophage-mediated pathophysiologic repair in chronically infarcted hearts. The company's pipeline includes epicardial patches and iPSC-derived cardiomyocyte patches, all built upon this same foundational immunomodulatory technology.

Differentiator

Problem solved

Functional benefit

Products and services

• Immunomodulatory Biologic Therapeutics Platform An adaptive biologic platform technology that redirects the immune system to restore organ function and improve quality of life, targeting diseases of aging, inflammation, and fibrosis. The platform serves as the foundation from which Avery Therapeutics develops specific therapeutic candidates.
• Bioengineered Epicardial Patch A biologically derived epicardial patch designed to induce macrophage-mediated pathophysiologic repair in chronically infarcted hearts. Indicated for treatment of chronic heart failure in patients requiring therapeutic options beyond traditional symptom-management approaches.
• iPSC-derived Cardiomyocyte Patches iPSC-derived cardiomyocyte patches utilizing tissue engineering approaches for heart failure treatment. Part of the company's pipeline leveraging its immunomodulatory platform technology.

Quantifiable outcome

• Peer-reviewed publications demonstrating efficacy in swine heart failure models and rat models
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Tenaya Therapeutics: Clinical-stage biotech developing gene therapies and iPSC-derived cardiomyocyte cell therapies for heart failure and genetic cardiomyopathies. Closely comparable modality and indication.
• Capricor Therapeutics: Clinical-stage biotech developing cell-based therapeutics (CAP-1002, cardiosphere-derived cells) for Duchenne muscular dystrophy and heart failure. Directly comparable therapeutic area and cell-therapy modality.
• Heartseed Inc. Japan-based clinical-stage developer of iPSC-derived cardiomyocyte cell therapy (HS-001) for heart failure. Closely comparable iPSC-cardiomyocyte approach.
• BioCardia: Clinical-stage developer of cell-based therapies for heart failure delivered via catheter-based systems (BCDA-04). Comparable cardiac cell therapy indication.
• Mesoblast: Commercial-stage cell therapy company with remestemcel-L and rexlemestrocel-L in cardiac and inflammatory indications. Comparable regenerative medicine/biologic platform targeting heart failure and inflammation.
• BlueRock Therapeutics: Clinical-stage iPSC-derived cell therapy company (Parkinson's, cardiology). Directly comparable to Avery as an iPSC-based therapeutic platform; acquired by Bayer for up to $1B. Board member Emile Nuwaysir led BlueRock from inception.
• Novoheart Holdings: Developer of human heart-in-a-jar bioengineered cardiac tissues and iPSC-based disease modeling for drug discovery. Comparable tissue engineering / iPSC cardiac platform.

Emerging players

• Lexeo Therapeutics: Clinical-stage gene therapy company with cardiac programs (Friedreich's ataxia cardiomyopathy, LX2004). Adjacent modality (gene therapy vs cell-based) in overlapping cardiac indications.
• Repairon GmbH: Preclinical-stage developer of engineered heart muscle (EHM) from iPSC-derived cardiomyocytes for heart failure. Closely comparable iPSC cardiac tissue engineering approach.

Broad incumbents

• Cytokinetics: Late-stage commercializing cardiovascular drug developer (omecamtiv mecarbil, aficamten). Larger incumbent pursuing cardiac contractility mechanisms for HCM and heart failure — same indication, different mechanism.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/averythera
• Xx.com/averythera

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avery Therapeutics, Inc.